What's up? Something is surely cooking... This 18% spike in SMMT stock price today on 20 times (2000%) volume is astonishing! This could not be simply because Summit CEO and Chairman Bob Duggan, a successful Pharma Executive, Scientologist, and Venture Capitalist invested another $50 million of his own money in this company. That is old news, the deal was completed one week ago, and cannot be the driver for today's stock action. Is something up with Ridinilazole?
Y
Summit Therapeutics is up 7.63% to 5.22
Y
Summit Therapeutics is down 13.44% to 4.25
J
Yahoo states that SMMT’s market cap is now $1.5 Billion. This sounds extraordinarily steep for this bio company (no, I’m not a short).
P
Something def happening
Y
Summit Therapeutics is up 6.20% to 3.94
Y
Summit Therapeutics is up 11.24% to 3.76
Y
@Yahoo Finance Insights. down 6.34%. thank you detective. it would be nice that you provide with some news as to why it is being sold. is it overvalue? is it bad management? is it bad financial? or is it something else?
Nearly all Sarepta followers saw this coming. More Bio Stocks™ Retweeted Bio Stocks™ $SMMT Ezutromid Development to be Discontinued.Bio Stocks™ added,
M
RMANF New Cannabis Alternative Jumps 21% during Mondays session Roadman Investments Investee Champignon Brands to Develop Mushroom-infused Cold Brew Coffee in Collaboration With Drip Coffee Social Ltd. In late September, RMANF announced that the Company’s investee Champignon Brands Inc. (“Champignon”) has entered into a Product Formulation and R&D Agreement (the “Agreement”) with Nanaimo, B.C. based Drip Coffee Social Ltd. (“Drip Coffee”). https://www.tradingview.com/chart/RMANF/aVxRVylL-RMANF-New-Cannabis-Alternative-Jumps-21-during-Mondays-session/
===================== Roadman Investments Corp. (RMANF) Alert Price: $0.0450 Investor Presentation Website | Recent News ======================== Members, As cannabis legalization spreads across the globe, another mind-altering drug is trying t
===================== Roadman Investments Corp. (RMANF) Alert Price: $0.0450 Investor Presentation Website | Recent News ======================== Members, As cannabis legalization spreads across the globe, another mind-altering drug is trying t
www.tradingview.com
m
Clearly the Investors at yesterday’s conference were not impressed with him. He should give up doing presentations and stop praising the competition.
H
EOY results now published on 11th April (this Wednesday) + CONFERENCE CALL
K
Mr Glyn Edwards, Chief Executive Officer of Summit, commented: “The strength of the interim data from our PhaseOut DMD trial has bolstered our belief that ezutromid could become a new standard of care for all patients with Duchenne muscular dystrophy (‘DMD’). Thats a pretty powerful statement.
H
Absolutely correct Mike ... I just took a look and analysts anticipating results 4th April.
m
Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Glyn Edwards, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on 21 June 2018 at 9:30am EDT in New York City.
m
Wow EOY results better than I thought, now for the CC
H
Here's a quick resume for NEW READERS! In terms of SMMT investment. What's clear - right here - right now, is that if you had $100 to invest today, Summit's current market cap of $220 million may well be worth $2 billion by end of year. ie if EZD 48 wk trials (results due July / Aug) simply follow on from 24 wk data (see results published in January) and EZD is taken to FDA who will likely approve it on qMR "endpoint" info alone, (See latest FDA approval terms for endorsement - MRI and biomarker info is now endpoint of choice) ... one can assume that the drug value would likely be $2 billion. I base this conservative figure on a company like Sarepta with a fix for only 13% DMD boys achieving mkt cap $5 Billion. Summit has a fix intended for 100% boys. However Summit have valued their treatment on the market at being around $100,000 per boy, per year as opposed to for example Sarepta who are currently charging $300,000 per boy per year. $2 billion is therefore a conservative comparison IMO.
If this drug is then made available for 100% of DMD boys and mrkt cap is say $2 billion ... investment of $100 would be X 10 by year end = $1000.
IMO the only risk folk are taking here is the very remote possibility that EZD 24 wk data was some fluke. (So there is a small risk still attached) We know the trial has been completed and NO safety issues. Just slight improvement in figures (continued build up off drug most likely to show improvement) will most likely result in a pass for qMR endpoint and in response the 6MWT and ambulatory functions will show actual positive effect. (Though as in Sarepta's case this was only shown to be tiny improvement at end of P2 ... not IMO relying on those figures which have historically been hard to show elsewhere)
We also know that this drug will in principle help Becker MD sufferers ... that's the same number of sufferers again. Summit will also carry on increasing in value as C Diff and Gonorrhea drugs complete trials. C Diff has already passed P2 and shown to be very best in class .... keeping thousands of people alive who simply go into hospitals and pick up C Diff whilst undergoing routine operations. C Diff P3 trials 2019. Over the next few years millions will die from this without help.
If I were to recommend someone investing $100 where to put it "right here - right now" ... there aren't many companies capable of such reward with this low risk. However ....DYOR.
H
<<>> So I decided to research companies that if one did enough homework, it might be possible to get good returns without suffering the problems involving international price of commodities which I did. I've not come across anything that's floated my boat like Summit ... flirted with IMM (lupus cure) but didn't stay in long as it didn't feel right and in the UK a company called Optibiotix which has an alternative fix to bringing down cholesterol. I had £5k in both for a while but after more and more research, I didn't like the fundamentals of their science and ended up over invested in Summit.
More
Bio Stocks™ Retweeted Bio Stocks™
$SMMT Ezutromid Development to be Discontinued.Bio Stocks™ added,
Roadman Investments Investee Champignon Brands to Develop Mushroom-infused Cold Brew Coffee in Collaboration With Drip Coffee Social Ltd.
In late September, RMANF announced that the Company’s investee Champignon Brands Inc. (“Champignon”) has entered into a Product Formulation and R&D Agreement (the “Agreement”) with Nanaimo, B.C. based Drip Coffee Social Ltd. (“Drip Coffee”).
https://www.tradingview.com/chart/RMANF/aVxRVylL-RMANF-New-Cannabis-Alternative-Jumps-21-during-Mondays-session/
If this drug is then made available for 100% of DMD boys and mrkt cap is say $2 billion ... investment of $100 would be X 10 by year end = $1000.
IMO the only risk folk are taking here is the very remote possibility that EZD 24 wk data was some fluke. (So there is a small risk still attached) We know the trial has been completed and NO safety issues. Just slight improvement in figures (continued build up off drug most likely to show improvement) will most likely result in a pass for qMR endpoint and in response the 6MWT and ambulatory functions will show actual positive effect. (Though as in Sarepta's case this was only shown to be tiny improvement at end of P2 ... not IMO relying on those figures which have historically been hard to show elsewhere)
We also know that this drug will in principle help Becker MD sufferers ... that's the same number of sufferers again. Summit will also carry on increasing in value as C Diff and Gonorrhea drugs complete trials. C Diff has already passed P2 and shown to be very best in class .... keeping thousands of people alive who simply go into hospitals and pick up C Diff whilst undergoing routine operations. C Diff P3 trials 2019. Over the next few years millions will die from this without help.
If I were to recommend someone investing $100 where to put it "right here - right now" ... there aren't many companies capable of such reward with this low risk. However ....DYOR.